EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas

Background: Anti-EGFR antibody therapy is still one of the clinical choices in head and neck squamous cell carcinoma (HNSCC) patients, but the emergence of cetuximab resistance questioned its effectiveness and reduced its applicability. Although several possible reasons of resistance against the ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelhűbel, Györgyi A., Cserepes, Mihály, Szabó, Balázs, Türk, Dóra, Kárpáti, Adél, Kenessey, István, Rásó, Erzsébet, Barbai, Tamás, Hegedűs, Zita, László, Viktória, Szokol, Bálint, Dobos, Judit, Őrfi, László, Tóvári, József
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Society Journal Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262169/
https://www.ncbi.nlm.nih.gov/pubmed/34257586
http://dx.doi.org/10.3389/pore.2021.620256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262169/
https://www.ncbi.nlm.nih.gov/pubmed/34257586
http://dx.doi.org/10.3389/pore.2021.620256

Ejemplares similares